Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sapna P Patel

Showing results (61-70 of 125) with videos related to

Pageof 13
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|April 29, 2026
CLO26-116: Epigenetic Modulation Using Combined oral Decitabine/Cedazuridine (DEC-C) and Nivolumab in Unresectable or Metastatic Mucosal Melanoma: A Phase Ib/II TrialJessica S W Borgers, Cheng-Chang Wu, Theresa M Medina, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 30, 2026
CLO26-116: Epigenetic Modulation Using Combined oral Decitabine/Cedazuridine (DEC-C) and Nivolumab in Unresectable or Metastatic Mucosal Melanoma: A Phase Ib/II TrialJessica S W Borgers, Cheng-Chang Wu, Theresa M Medina, et al.
The American Journal of Dermatopathology|June 5, 2018
Case Report of Myeloid Sarcoma Masquerading as In-Transit Metastasis at a Previous Melanoma Site: Avoiding a Diagnostic PitfallJonathan L Curry, Michael T Tetzlaff, Sa A Wang, et al.
British Journal of Cancer|October 11, 2024
Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanomaChandrani Chattopadhyay, Janos Roszik, Rajat Bhattacharya, et al.
Cancer|October 29, 2020
Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancersFilip Janku, Divya Sakamuri, Shumei Kato, et al.
JAMA Oncology|November 23, 2022
Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical TrialJoseph M Unger, Amy Darke, Megan Othus, et al.
ESMO Open|February 2, 2018
Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2Isabella C Glitza, Michelle Rohlfs, Nandita Guha-Thakurta, et al.
Journal for Immunotherapy of Cancer|November 18, 2020
Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapyYong Qin, Kathryn Bollin, Mariana Petaccia de Macedo, et al.
Journal for Immunotherapy of Cancer|February 20, 2019
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibitionElizabeth I Buchbinder, Janice P Dutcher, Gregory A Daniels, et al.
Journal for Immunotherapy of Cancer|August 21, 2023
T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapyBettzy Stephen, Joud Hajjar, Shrutii Sarda, et al.
Pageof 13

Showing results (61-70 of 125) with videos related to

Sort By:
Pageof 13
Journal of the National Comprehensive Cancer Network : JNCCN|April 29, 2026
CLO26-116: Epigenetic Modulation Using Combined oral Decitabine/Cedazuridine (DEC-C) and Nivolumab in Unresectable or Metastatic Mucosal Melanoma: A Phase Ib/II TrialJessica S W Borgers, Cheng-Chang Wu, Theresa M Medina, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 30, 2026
CLO26-116: Epigenetic Modulation Using Combined oral Decitabine/Cedazuridine (DEC-C) and Nivolumab in Unresectable or Metastatic Mucosal Melanoma: A Phase Ib/II TrialJessica S W Borgers, Cheng-Chang Wu, Theresa M Medina, et al.
The American Journal of Dermatopathology|June 5, 2018
Case Report of Myeloid Sarcoma Masquerading as In-Transit Metastasis at a Previous Melanoma Site: Avoiding a Diagnostic PitfallJonathan L Curry, Michael T Tetzlaff, Sa A Wang, et al.
British Journal of Cancer|October 11, 2024
Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanomaChandrani Chattopadhyay, Janos Roszik, Rajat Bhattacharya, et al.
Cancer|October 29, 2020
Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancersFilip Janku, Divya Sakamuri, Shumei Kato, et al.
JAMA Oncology|November 23, 2022
Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical TrialJoseph M Unger, Amy Darke, Megan Othus, et al.
ESMO Open|February 2, 2018
Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2Isabella C Glitza, Michelle Rohlfs, Nandita Guha-Thakurta, et al.
Journal for Immunotherapy of Cancer|November 18, 2020
Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapyYong Qin, Kathryn Bollin, Mariana Petaccia de Macedo, et al.
Journal for Immunotherapy of Cancer|February 20, 2019
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibitionElizabeth I Buchbinder, Janice P Dutcher, Gregory A Daniels, et al.
Journal for Immunotherapy of Cancer|August 21, 2023
T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapyBettzy Stephen, Joud Hajjar, Shrutii Sarda, et al.
Pageof 13